{"classes":[{"categories":[{"measurements":[{"comment":"Median was not reached due to insufficient number of events, i.e., (too few participants had reached progression at data cutoff.)","groupId":"OG000","lowerLimit":"4.0","upperLimit":"77.4","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Survival curves for DOR will be estimated using the Kaplan-Meier method.","dispersionType":"Full Range","groups":[{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression\\* or unacceptable toxicity.\n\n\\* NOTE: Patients with confirmed disease progression may continue to receive treatment if they are otherwise clinically stable until there is an increase in tumor burden of 25% or more following initial confirmation of progression. Under exceptional circumstances, and with protocol P.I. and CITN P.I. approval, patients may receive treatment beyond 2 years.\n\nLaboratory Biomarker Analysis: Ancillary studies\n\nPembrolizumab: Given IV","id":"OG000","title":"Treatment (Pembrolizumab)"}],"paramType":"MEDIAN","populationDescription":"Thirty participants with durable response were assessed by RECIST 1.1.","reportingStatus":"POSTED","timeFrame":"Time interval between the date of first response (CR/PR) and the date of progression, assessed up to 3 years","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}